In the context of radiotherapy, it has been found that OIP5‐AS1 affects radiosensitivity via the tumour suppressor DYRK1A; OIP5‐AS1 and DYRK1A are crucial molecular players in the inhibition of cell survival and promotion of apoptosis, leading to increased radiosensitivity in colorectal cancer cells, with the potential to improve outcomes for osteosarcoma via radiotherapy.24 Here, OIP5 is linked to neoplasm.